Highbridge reports 9.1% TuHURA stake via warrants

TuHURA Biosciences, Inc. reported that Highbridge Capital Management, LLC has become a significant holder of its common stock through warrants.

Rhea-AI Filing Summary

TuHURA Biosciences, Inc. reported that Highbridge Capital Management, LLC has become a significant holder of its common stock through warrants. Highbridge reports beneficial ownership of 6,060,608 shares of TuHURA common stock, all issuable upon exercise of warrants held by funds and accounts it advises.

This position represents 9.1% of TuHURA’s common stock, calculated using 60,720,508 shares outstanding as of December 10, 2025, after a recently completed offering and assuming warrant exercise. Highbridge has sole voting and dispositive power over these warrant shares and is filing as an investment adviser.

The filing states the securities were acquired and are held in the ordinary course of business, not with the purpose or effect of changing or influencing control of TuHURA. Highbridge Tactical Credit Master Fund, L.P., one of the advised funds, has rights over more than 5% of the outstanding shares.

Insights

Equity ownership & governance analyst

Highbridge reports a 9.1% economic stake in TuHURA via warrants, as a passive, ordinary-course investment.

The filing shows Highbridge Capital Management, as investment adviser to the Highbridge Funds, reporting beneficial ownership of 6,060,608 TuHURA shares issuable upon warrant exercise. This translates to 9.1% of the company’s common stock based on December 10, 2025 figures.

Highbridge has sole voting and dispositive power over these warrant shares, indicating centralized control of this position. However, the certification explicitly states the holdings are in the ordinary course of business and not intended to change or influence control of TuHURA Biosciences.

Highbridge Tactical Credit Master Fund, L.P. has rights over more than 5% of the outstanding shares, highlighting it as the key underlying holder. Actual market impact will depend on future warrant exercise and any subsequent trading activity, which are not detailed in the document.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in TuHURA Biosciences (HURA) does Highbridge Capital Management report?

Highbridge Capital Management reports beneficial ownership of 6,060,608 TuHURA common shares, all issuable upon exercise of warrants. This represents 9.1% of the company’s common stock, based on 60,720,508 shares outstanding as of December 10, 2025, after a completed offering.

How does Highbridge’s 9.1% ownership in TuHURA (HURA) arise?

Highbridge’s 9.1% interest comes entirely from warrants held by funds and accounts it advises. These warrants are exercisable into 6,060,608 TuHURA common shares, giving Highbridge beneficial ownership with sole voting and dispositive power over those potential shares under the Schedule 13G filing.

Is Highbridge Capital Management a passive investor in TuHURA Biosciences (HURA)?

The certification states the securities were acquired and are held in the ordinary course of business, not to change or influence control of TuHURA. The filing is on Schedule 13G, which is generally used by passive investors rather than activists seeking control changes.

Which Highbridge fund holds more than 5% of TuHURA (HURA) shares?

Highbridge Tactical Credit Master Fund, L.P., one of the Highbridge Funds, has the right to receive or direct dividends or sale proceeds from more than 5% of TuHURA’s outstanding common stock, according to the ownership disclosure in Item 6 of the Schedule 13G filing.

What does sole voting and dispositive power mean in Highbridge’s TuHURA (HURA) filing?

Highbridge reports sole power to vote and dispose of the 6,060,608 warrant shares. This means Highbridge alone decides how these securities are voted and whether or when they might be sold, even though they are held for the benefit of the Highbridge Funds.

On what share count is Highbridge’s 9.1% TuHURA (HURA) stake calculated?

The 9.1% figure is based on 60,720,508 TuHURA common shares as of December 10, 2025. That total comes from a prospectus filed under Rule 424(b)(5), reflecting shares outstanding after a completed offering and assuming exercise of Highbridge’s warrants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:18 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

TuHURA Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

898920103

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 898920103

1

Names of Reporting Persons

Highbridge Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,060,608.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,060,608.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,060,608.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.1 %

12

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: The 6,060,608 shares of Common Stock (as defined in Item 2(a)) are issuable upon exercise of warrants.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TuHURA Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 10500 University Center Dr., Suite 110, Tampa, FL 33612
Item 2.
(a)	Name of person filing: This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of TuHURA Biosciences, Inc., a Nevada corporation (the "Issuer"), issuable upon exercise of warrants directly held by the Highbridge Funds. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of the Reporting Person is 390 Madison Avenue, 28th Floor, New York, NY 10017.
(c)	Citizenship: Highbridge is a Delaware limited liability company.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 898920103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 60,720,508 shares of Common Stock as of December 10, 2025 as reported in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on December 10, 2025, after giving effect to the completion of the offering as described therein, and assumes the exercise of the warrants held by the Highbridge Funds.
(b)	Percent of class: 9.1%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Highbridge Tactical Credit Master Fund, L.P., a Highbridge Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the outstanding shares of Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Highbridge Capital Management, LLC

Signature:	/s/ Kirk Rule
Name/Title:	Kirk Rule, Executive Director
Date:	02/17/2026